The latest round of the UK government’s Commercialising Quantum Technologies challenge awarded Riverlane a total of £2.5 million for its projects. Starting in 2022, a total of four initiatives will engage with hardware and enterprise partners to address the significance of the scientific and engineering challenges that must be overcome first in order to pave the way for quantum computers.
Developing an error-corrected quantum processor solution for commercial quantum computing
The Riverlane project will be on the integration of quantum error correction on a trapped ion quantum computer. This will be the critical process in the creation of fault-tolerant quantum computer capable of a range of transformative applications. The project will be collaborated by Universal Quantum, Imperial College London, University of Sussex, Science and Technology Facilities Council (STFC) Hartree Centre, Edwards, TMD Technologies, Diamond Microwave, Sia Partners and Qureca.
Quantum enhanced computing platform for pharmaceutical R&D (QuPharma)
This is project will focus on the pharmaceutical industry wherein quantum algorithms and quantum chemistry methods will be developed to help understand chemical processes in line for drug research and development. This will be a step forward towards the adoption of quantum computers in designing medicines. This will be collaborated by SEEQC, STFC Laboratories, University of Oxford, Medicines Discovery Catapult & Merck.
The quantum data center of the future
This project will handle the development of the software modules and design a blueprint for quantum data centre in the future. This will be a hub for quantum data, storing and processing will be more accessible with less power than the current alternatives. ORCA Computing, University of Bath, University of Bristol, Imperial College London, University College London, University of Southampton, NCC Operations, BT, PQShield, Digital Catapult, Kets Quantum Security, BP & NCC Group will be working on the project.
Practical improvements to the performance of quantum simulation for drug-protein binding
This project will focus on exploration of the ‘hows’ of an error-correcting quantum processor in the area of protein binding. This project will initiate drug designing quantum computers. Rigetti and Astex will work on the project.
Read more about the news here.